Generics BulletinDr Reddy’s has gained rights to a pair of proposed Stelara (ustekinumab) and Simponi (golimumab) biosimilars in multiple markets in south-east Asia, after striking an exclusive commercialization agree
ScripEli Lilly’s blockbuster obesity and type 2 diabetes therapy, Mounjaro (tirzepatide) has made its India debut throwing down the gauntlet to rival Novo Nordisk, currently in the wings with Wegovy (injec
Generics BulletinAlvotech’s AVT03 proposed biosimilar to Prolia/Xgeva (denosumab) has been successfully filed by its partner Dr Reddy’s Laboratories with the US Food and Drug Administration, in the latest development
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Deal Brings AstraZeneca Greater C